Literature DB >> 27659045

IGFBP2 Activates the NF-κB Pathway to Drive Epithelial-Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma.

Song Gao1,2, Yan Sun3, Xuebin Zhang4, Limei Hu1, Yuexin Liu1, Corrine Yingxuan Chua1, Lynette M Phillips1, He Ren2, Jason B Fleming5, Huamin Wang1, Paul J Chiao6, Jihui Hao7, Wei Zhang8,6,9.   

Abstract

The molecular basis underlying the particularly aggressive nature of pancreatic ductal adenocarcinoma (PDAC) still remains unclear. Here we report evidence that the insulin-like growth factor-binding protein IGFBP2 acts as a potent oncogene to drive its extremely malignant character. We found that elevated IGFBP2 expression in primary tumors was associated with lymph node metastasis and shorter survival in patients with PDAC. Enforced expression of IGFBP2 promoted invasion and metastasis of PDAC cells in vitro and in vivo by inducing NF-κB-dependent epithelial-mesenchymal transition (EMT). Mechanistic investigations revealed that IGFBP2 induced the nuclear translocation and phosphorylation of the p65 NF-κB subunit through the PI3K/Akt/IKKβ pathway. Conversely, enforced expression of PTEN blunted this signaling pathway and restored an epithelial phenotype to PDAC cells in the presence of overexpressed IGFBP2. Overall, our results identify IGFBP2 as a pivotal regulator of an EMT axis in PDAC, the activation of which is sufficient to confer the characteristically aggressive clinical features of this disease. Cancer Res; 76(22); 6543-54. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27659045      PMCID: PMC5315491          DOI: 10.1158/0008-5472.CAN-16-0438

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

Review 1.  NF-kappaB and epithelial to mesenchymal transition of cancer.

Authors:  Chengyin Min; Sean F Eddy; David H Sherr; Gail E Sonenshein
Journal:  J Cell Biochem       Date:  2008-06-01       Impact factor: 4.429

Review 2.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

Review 3.  Role of the insulin-like growth factor family in cancer development and progression.

Authors:  H Yu; T Rohan
Journal:  J Natl Cancer Inst       Date:  2000-09-20       Impact factor: 13.506

4.  Quantitative proteomic profiling of pancreatic cancer juice.

Authors:  Ru Chen; Sheng Pan; Eugene C Yi; Samuel Donohoe; Mary P Bronner; John D Potter; David R Goodlett; Ruedi Aebersold; Teresa A Brentnall
Journal:  Proteomics       Date:  2006-07       Impact factor: 3.984

5.  IGF binding protein 2 supports the survival and cycling of hematopoietic stem cells.

Authors:  Hoangdinh Huynh; Junke Zheng; Masato Umikawa; Chaozheng Zhang; Robert Silvany; Satoru Iizuka; Martin Holzenberger; Wei Zhang; Cheng Cheng Zhang
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

6.  Role of the IkappaB kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells.

Authors:  M Arsura; F Mercurio; A L Oliver; S S Thorgeirsson; G E Sonenshein
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

7.  Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer.

Authors:  Jyh-Ming Liou; Chia-Tung Shun; Jin-Tung Liang; Han-Mo Chiu; Mei-Jyh Chen; Chien-Chuan Chen; Hsiu-Po Wang; Ming-Shiang Wu; Jaw-Town Lin
Journal:  J Clin Endocrinol Metab       Date:  2010-02-15       Impact factor: 5.958

8.  Insulin-like growth factor (IGF) binding protein 2 functions coordinately with receptor protein tyrosine phosphatase β and the IGF-I receptor to regulate IGF-I-stimulated signaling.

Authors:  Xinchun Shen; Gang Xi; Laura A Maile; Christine Wai; Clifford J Rosen; David R Clemmons
Journal:  Mol Cell Biol       Date:  2012-08-06       Impact factor: 4.272

9.  IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas.

Authors:  Lynette M Moore; Kristen M Holmes; Sarah M Smith; Ying Wu; Elena Tchougounova; Lene Uhrbom; Raymond Sawaya; Janet M Bruner; Gregory N Fuller; Wei Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-16       Impact factor: 11.205

10.  IGFBP2 potentiates nuclear EGFR-STAT3 signaling.

Authors:  C Y Chua; Y Liu; K J Granberg; L Hu; H Haapasalo; M J Annala; D E Cogdell; M Verploegen; L M Moore; G N Fuller; M Nykter; W K Cavenee; W Zhang
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

View more
  40 in total

1.  IGFBP2 promotes vasculogenic mimicry formation via regulating CD144 and MMP2 expression in glioma.

Authors:  Y Liu; F Li; Y T Yang; X D Xu; J S Chen; T L Chen; H J Chen; Y B Zhu; J Y Lin; Y Li; X M Xie; X L Sun; Y Q Ke
Journal:  Oncogene       Date:  2018-10-27       Impact factor: 9.867

Review 2.  Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer.

Authors:  A Fucic; A Aghajanyan; Z Culig; N Le Novere
Journal:  Pathol Oncol Res       Date:  2018-09-16       Impact factor: 3.201

Review 3.  IGFBP2: integrative hub of developmental and oncogenic signaling network.

Authors:  Tao Li; M Elizabeth Forbes; Gregory N Fuller; Jiabo Li; Xuejun Yang; Wei Zhang
Journal:  Oncogene       Date:  2020-01-10       Impact factor: 9.867

4.  IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway.

Authors:  Longhao Sun; Xuebin Zhang; Qianqian Song; Liang Liu; Elizabeth Forbes; Weijun Tian; Zhixiang Zhang; Ya'an Kang; Huamin Wang; Jason B Fleming; Boris C Pasche; Wei Zhang
Journal:  Cancer Lett       Date:  2020-12-10       Impact factor: 8.679

5.  ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.

Authors:  Kejun Liu; Xianwen Chen; Ligang Wu; Shiyuan Chen; Nianxin Fang; Limin Cai; Jun Jia
Journal:  BMC Pulm Med       Date:  2021-05-15       Impact factor: 3.317

6.  ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2.

Authors:  Rozita Bagheri-Yarmand; Ramona Dadu; Lei Ye; Yaashmin Shiny Jebaraj; Jade A Martinez; Junsheng Ma; Rohinton S Tarapore; Joshua E Allen; Steven I Sherman; Michelle D Williams; Robert F Gagel
Journal:  Mol Cancer Ther       Date:  2021-02-03       Impact factor: 6.009

Review 7.  For robust big data analyses: a collection of 150 important pro-metastatic genes.

Authors:  Yan Mei; Jun-Ping Yang; Chao-Nan Qian
Journal:  Chin J Cancer       Date:  2017-01-21

8.  Long non-coding RNA HOTAIR promotes cell migration by upregulating insulin growth factor-binding protein 2 in renal cell carcinoma.

Authors:  Hiromichi Katayama; Keiichi Tamai; Rie Shibuya; Mao Nakamura; Mai Mochizuki; Kazunori Yamaguchi; Sadafumi Kawamura; Tatsuo Tochigi; Ikuro Sato; Takamasa Okanishi; Kunie Sakurai; Wataru Fujibuchi; Yoichi Arai; Kennichi Satoh
Journal:  Sci Rep       Date:  2017-09-20       Impact factor: 4.379

9.  ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer.

Authors:  Armen Gharibi; Sa La Kim; Justin Molnar; Daniel Brambilla; Yvess Adamian; Malachia Hoover; Julie Hong; Joy Lin; Laurelin Wolfenden; Jonathan A Kelber
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

10.  Centrosomal protein 55 activates NF-κB signalling and promotes pancreatic cancer cells aggressiveness.

Authors:  Tao Peng; Wei Zhou; Feng Guo; He-Shui Wu; Chun-You Wang; Li Wang; Zhi-Yong Yang
Journal:  Sci Rep       Date:  2017-07-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.